Navigation Links
Tengion Appoints A. Brian Davis Chief Financial Officer
Date:8/2/2010

EAST NORRITON, Pa., Aug. 2 /PRNewswire-FirstCall/ -- Tengion Inc. (Nasdaq: TNGN) today announced that it has appointed A. Brian Davis to the position of Chief Financial Officer.  Mr. Davis comes to Tengion after 15 years with Neose Technologies, Inc., a biopharmaceutical company using enzymatic technologies to develop improved protein therapeutics. At its peak, Neose employed 200 individuals, including cGMP production, development and research personnel at three sites. 

"Brian's demonstrated excellence as a public biotech company CFO, his strong accounting and finance background, and his experience supporting financial evaluation of business development transactions will be valuable to Tengion as we continue to advance the company and our product candidates," stated Steven Nichtberger, M.D., President and Chief Executive Officer of Tengion.

Mr. Davis advanced from Controller to SVP and CFO at Neose, and brings highly relevant experience to Tengion including raising over $300 million in public and private equity and debt, financial evaluation of business development transactions, treasury and cash management, SEC reporting, Sarbanes-Oxley compliance, and investor relations.  Mr. Davis holds a BS in Accounting from Trenton State College and an MBA from the Wharton School of the University of Pennsylvania. He is a Certified Public Accountant.

Linda Hearne, Tengion's Vice President, Finance, will be stepping down from her role in order to relocate with her family overseas.  "During her nearly six years with Tengion, Linda has played a defining role in the development of our finance function and was instrumental in our becoming a public company earlier this year.  We wish Linda and her family all the best in their new life abroad and we are grateful that she will remain with Tengion in the coming weeks to ensure a smooth transition," said Dr. Nichtberger.  

About Tengion

Tengion, a clinical-stage biotechnology company, has pioneered the Organ Regeneration Platform that enables us to create proprietary product candidates that are intended to harness the intrinsic regenerative pathways of the body to produce a range of native-like organs and tissues. Our product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. Tengion commenced a Phase I clinical trial in the first half of 2010 for its lead product candidate, the Neo-Urinary Conduit™, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal. Tengion has also applied its technology in two Phase II clinical trials for Tengion's Neo-Bladder Augment™ for the treatment of neurogenic bladder and is in pre-clinical development of its Neo-Kidney Augment™. Tengion has worldwide rights to its product candidates.


'/>"/>
SOURCE Tengion Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Tengion Presents New Data Supporting its Organ Regeneration Platform™ at 8th Annual Meeting of the International Society for Stem Cell Research
2. Tengion Presents New Data Supporting Key Urologic and Kidney Programs at 16th Annual Meeting of the International Society for Cellular Therapy
3. Tengion to Present at the Piper Jaffray 20th Annual Healthcare Conference
4. Tengion Announces Second Closing of Series C Financing
5. Tengion Featured as Model of Innovation and Success at 35th Anniversary Celebration of the National Venture Capital Association
6. Tengion Scientists Publish Positive Preclinical Findings With Neo-Organ Demonstrating Long-term Durability and Growth With Skeletal Maturation
7. CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO
8. Adeona Appoints Julie A. Caudill, B.B.A., Vice President of Finance and Corporate Controller
9. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
10. SemBioSys Appoints President of US and International Operations and Announces the Appointments of Three Vice Presidents
11. Biostar Pharmaceuticals, Inc. Appoints New Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... , May 23, 2016 Zimmer Biomet Holdings, ... healthcare, today announced that its Board of Directors has approved ... the second quarter of 2016. The cash ... about July 29, 2016 to stockholders of record as of ... of dividends are subject to approval of the Board of ...
(Date:5/23/2016)... Alto, CA (PRWEB) , ... May 23, 2016 ... ... and public interest organization focused on molecular nanotechnology, announced the winners for the ... of pioneer physicist Richard Feynman, are given in two categories, one for experiment ...
(Date:5/20/2016)... ... 20, 2016 , ... Korean researchers say Manumycin A triggers apoptosis, or natural ... to treat the disease. Surviving Mesothelioma has just posted an article on the new ... institutions based their mesothelioma study on the fact the Manumycin A, a derivative of ...
(Date:5/19/2016)... 19, 2016 There is no ... given the relentless pressures in pricing and lack in ... investors circle though - numerous opportunities are up for ... session, ActiveWallSt.com,s presents four names in this sector: Portola ... Inc. (NASDAQ: VTAE ), Anthera Pharmaceuticals Inc. ...
Breaking Biology Technology:
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:3/31/2016)... March 31, 2016   ... or the "Company") LegacyXChange is excited to ... its soon to be launched online site for trading ... ) will also provide potential shareholders a sense ... technology to an industry that is notorious for fraud. ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
Breaking Biology News(10 mins):